CLBS - Caladrius Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.45
-0.15 (-2.68%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.60
Open0.00
Bid0.00 x 0
Ask7.49 x 4000
Day's Range5.30 - 5.66
52 Week Range2.63 - 11.65
Volume68,012
Avg. Volume327,447
Market Cap52.156M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateAug 8, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.50
Trade prices are not sourced from all markets
  • ACCESSWIRElast month

    Today's Research Reports on Stocks to Watch: Sarepta Therapeutics and Caladrius Biosciences

    NEW YORK, NY / ACCESSWIRE / June 20, 2018 / It was a day of big gains for biotech stocks Sarepta Therapeutics and Caladrius Biosciences on Tuesday. Sarepta soared almost 37% on positive interim data on ...

  • GlobeNewswirelast month

    Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina

    Caladrius Biosciences, Inc. (CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases, announces today that the U.S. Food and Drug Administration (“FDA”) has granted regenerative medicine advanced therapy (“RMAT”) designation to the Company’s late-stage CD34+ cell therapy program for the treatment of refractory angina.

  • GlobeNewswire2 months ago

    Caladrius Biosciences Sells Rights to Counter-Flow Centrifugation System to Hitachi Chemical Advanced Therapeutics Solutions

    Caladrius Biosciences, Inc. (CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces today that the Company has sold for $2.5 million its ownership interest in a development-stage, fully enclosed, automated, programmable counter-flow centrifugation (“CFC”) system for use in cell therapy manufacturing to Hitachi Chemical Advanced Therapeutics Solutions, LLC (“HCATS”), previously known as PCT Cell Therapy Services, LLC. The CFC system enables cell therapy developers to wash and concentrate cells in an enclosed environment.

  • GlobeNewswire2 months ago

    Caladrius Biosciences Reports 2018 First Quarter Financial Results

    BASKING RIDGE, N.J., May 10, 2018-- Caladrius Biosciences, Inc., a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, ...

  • Market Exclusive2 months ago

    For Diabetes Patients, Management Solutions Are As Critical As Medications

    For diabetes sufferers, it’s not just effective medications that are necessary, but effective self-management. The challenge with diabetes, both type 1 and type 2, is not necessarily that the medications we have available today are just not good enough. The problem is, the disease has to be managed constantly, from the moment you wake up […] The post For Diabetes Patients, Management Solutions Are As Critical As Medications appeared first on Market Exclusive.

  • GlobeNewswire3 months ago

    Caladrius Biosciences to Participate at the 15th International Symposium on Cardiovascular Regeneration and Repair

    BASKING RIDGE, N.J., May 07, 2018-- Caladrius Biosciences, Inc., a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, ...

  • GlobeNewswire3 months ago

    Caladrius Biosciences to Host First Quarter 2018 Financial Results Conference Call on Thursday, May 10, 2018 at 4:30 p.m. Eastern Time

    Caladrius Biosciences, Inc. (CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiology indications, announces that the Company will release financial results for the three months ended March 31, 2018 after close of the U.S. financial markets on Thursday, May 10, 2018. Caladrius’ management will host a conference call for the investment community beginning at 4:30 p.m. ET on Thursday, May 10, 2018 to discuss the financial results, provide a company update and answer questions. Shareholders and other interested parties may participate in the conference call by dialing (866) 595-8403 (domestic), or (706) 758-9979 (international), and providing conference ID: 9763239.

  • ACCESSWIRE3 months ago

    Wired News - Mesoblast Announced Updated Data from Phase-3 and Phase-2b Clinical Trials of MPC-150-IM in Patients with Chronic Heart Failure

    Stock Monitor: Caladrius Biosciences Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 20, 2018 / Active-Investors.com has just released a free research report on Mesoblast Ltd (NASDAQ: MESO ). If ...

  • ACCESSWIRE4 months ago

    Caladrius Biosciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 22, 2018 / Caladrius Biosciences, Inc. (NASDAQ: CLBS ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 22, 2018, at 4:30 PM Eastern ...

  • ACCESSWIRE8 months ago

    Caladrius Biosciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 9, 2017 / Caladrius Biosciences, Inc. (NASDAQ: CLBS ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 9, 2017 at 4:30 PM ...

  • What Is Caladrius Biosciences Inc’s (CLBS) Share Price Doing?
    Simply Wall St.8 months ago

    What Is Caladrius Biosciences Inc’s (CLBS) Share Price Doing?

    Caladrius Biosciences Inc (NASDAQ:CLBS), a biotechnology company based in United States, saw a double-digit share price rise of over 10% in the past couple of months on the NasdaqCM. AsRead More...